Robert I Glazer

List of Publications by Year
in descending order

32 papers	2,750 citations	430874 18 h-index	477307 29 g-index
34 all docs	34 docs citations	34 times ranked	4452 citing authors

#	Article	IF	Citations
1	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology, 2007, 8, R76.	9.6	1,009
2	An invasion-related complex of cortactin, paxillin and PKCÎ¼ associates with invadopodia at sites of extracellular matrix degradation. Oncogene, 1999, 18, 4440-4449.	5.9	334
3	Sex Hormones Prolong the QT Interval and Downregulate Potassium Channel Expression in the Rabbit Heart. Circulation, 1996, 94, 1471-1474.	1.6	323
4	3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study. ACS Applied Materials & Interfaces, 2016, 8, 30017-30026.	8.0	234
5	3D printed nanocomposite matrix for the study of breast cancer bone metastasis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 69-79.	3.3	162
6	Peroxisome Proliferator-Activated Receptor Î´ and Î³ Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis. Cancer Research, 2005, 65, 3950-3957.	0.9	99
7	Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)â€“dependent TGF-Î² signaling. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7820-7825.	7.1	66
8	Antisense Expression of Protein Kinase CÎ± Inhibits the Growth and Tumorigenicity of Human Glioblastoma Cells. Neurosurgery, 1994, 35, 904-909.	1.1	54
9	PPARÎ´ Induces Estrogen Receptor-Positive Mammary Neoplasia through an Inflammatory and Metabolic Phenotype Linked to mTOR Activation. Cancer Research, 2013, 73, 4349-4361.	0.9	52
10	Musashi1: an RBP with versatile functions in normal and cancer stem cells. Frontiers in Bioscience - Landmark, 2012, 17, 54.	3.0	50
11	Engineering a Novel 3D Printed Vascularized Tissue Model for Investigating Breast Cancer Metastasis to Bone. Advanced Healthcare Materials, 2020, 9, e1900924.	7.6	45
12	Musashi1: A stem cell marker no longer in search of a function. Cell Cycle, 2008, 7, 2635-2639.	2.6	41
13	PPARÎ´ Activation Acts Cooperatively with 3-Phosphoinositide-Dependent Protein Kinase-1 to Enhance Mammary Tumorigenesis. PLoS ONE, 2011, 6, e16215.	2.5	40
14	Inhibition of Peroxisome Proliferator-Activated Receptor Î³ Increases Estrogen Receptorâ€“Dependent Tumor Specification. Cancer Research, 2009, 69, 687-694.	0.9	39
15	3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-Î³ and Promotes Adipocyte Differentiation. Molecular Endocrinology, 2006, 20, 268-278.	3.7	34
16	Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated ReceptorÎ´ Activation. PPAR Research, 2010, 2010, 1-12.	2.4	33
17	PPARÎ³and PPARÎ´as Modulators of Neoplasia and Cell Fate. PPAR Research, 2008, 2008, 1-8.	2.4	19
18	PLAC1 as a serum biomarker for breast cancer. PLoS ONE, 2018, 13, e0192106.	2.5	19

#	Article	IF	Citations
19	Multifactorial Analysis of Conditional Reprogramming of Human Keratinocytes. PLoS ONE, 2015, 10, e0116755.	2.5	18
20	Drug-Targeted Inhibition of Peroxisome Proliferator-Activated ReceptorÎ³ Enhances the Chemopreventive Effect of Anti-Estrogen. Oncotarget, 2012, 3, 345-358.	1.8	18
21	Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis. Scientific Reports, 2018, 8, 5717.	3.3	13
22	Stem Cell Antigen-1 Deficiency Enhances the Chemopreventive Effect of Peroxisome Proliferatorâ€“Activated ReceptorÎ³ Activation. Cancer Prevention Research, 2012, 5, 51-60.	1.5	12
23	Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs. Antiviral Chemistry and Chemotherapy, 2015, 24, 19-27.	0.6	10
24	Mammary stem and progenitor cell regulation. Cancer Biomarkers, 2007, 3, 171-181.	1.7	6
25	PPARÎ´as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance. PPAR Research, 2016, 2016, 1-7.	2.4	6
26	Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist. PLoS ONE, 2021, 16, e0248996.	2.5	5
27	A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. Oncotarget, 2010, 1, 470-1.	1.8	5
28	MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment. Oncotarget, 2018, 9, 8042-8053.	1.8	3
29	Georgetown Faculty Grievance. Science, 1999, 283, 487-487.	12.6	1
30	Stem cell antigenâ€1 (Scaâ€1) disrupts GDF10/TGFâ€Î²2 signal transduction at the plasma membrane to regulate Smad2/3 nuclear signaling. FASEB Journal, 2011, 25, 243.5.	0.5	0
31	Cellular Reprogramming of Epithelial Cells Leading to Conditional Immortalization is Accompanied by Changes in Multiple Pathways. FASEB Journal, 2015, 29, 670.6.	0.5	0
32	PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. Oncotarget, 2017, 8, 50337-50341.	1.8	0